At the same time, AstraZeneca also launched its latest triple therapy, Breztri Aerosphere® to cater to the unmet needs of patients living with chronic obstructive pulmonary disease (COPD).

The updated savings scheme will encompass several key products in AstraZeneca’s US inhaled respiratory medicines lineup, ...

Breztri Aerosphere; and Symbicort. The cap would not apply to co-pays for people enrolled in federal government insurance programs, AstraZeneca said. AstraZeneca also noted that it had ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

AstraZeneca's (AZ) $1.15 billion bet on Pearl Therapeutics may soon produce returns after lung drug Bevespi Aerosphere (glycopyrrolate+formoterol fumarate) was approved by the US Food and Drug ...

AstraZeneca Pharma India Ltd said that the company has secured permission from the Drugs Controller General of India (DCGI) for the import and market of Breztri Aerosphere, an inhalation ...

Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...

AstraZeneca Pharma: The pharmaceutical company will launch Breztri Aerosphere in January 2025 in India. Breztri Aerosphere is used to relieve symptoms and prevent exacerbations in adult patients ...